Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
Chronic fatigue syndrome/myalgic encephalomyelitis (ME/CFS) is an unexplained
multisymptom/multisystem disorder for which there are currently no validated treatments. The
present exploratory clinical trial aims to advance our understand of the mechanisms of in
situ GSH synthesis control through assessment of the response of brain GSH and plasma markers
of oxidative stress to different doses of NAC in comparison to placebo, as a potential
treatment for ME/CFS that would provide neuroprotection against oxidative stress by restoring
cortical GSH reserves. If successful, this exploratory clinical trial would address a
significant public health concern by shedding new light onto the mechanisms of action of NAC
in brain GSH restoration, which could open a new avenue for the development of potentially
effective treatments for a disorder, ME/CFS, that currently has none.
Phase:
Phase 2
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)